ScienceDaily
•Read full article
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.
The immunotherapy created an immune response against cancer and was well tolerated, with adverse events including fatigue, injection site pain and fever.
The mRNA immunotherapy is targeted for patients with lung cancer, melanoma and other solid tumours.